The Lancet Haematology: PET-CT predicts lymphoma survival better than conventional imaging

September 17, 2014

Positron emission tomography/computed tomography (PET-CT) is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma, and should be used routinely in clinical practice, according to new research published in The Lancet Haematology.

"Our findings have important implications for patients with follicular lymphoma, a common and usually slow-growing lymphoma. Compared to conventional CT scanning, PET-CT is more accurate in mapping-out the lymphoma, and better identifies the majority of patients who have a prolonged remission after treatment"*, explains Professor Judith Trotman, study leader and Associate Professor at Concord Hospital, University of Sydney, Australia.

Almost all patients with follicular lymphoma, a common type of non-Hodgkin lymphoma, respond very well to initial treatment with immunochemotherapy, but relapse is common. Current practice is to use CT imaging to evaluate treatment response. However CT cannot easily distinguish patients who are likely to remain in a prolonged remission for several years from those at high risk of early relapse. This creates considerable uncertainty for patients.

PET-CT is performed using a very small amount of a tracer called 18F-fluorodeoxyglucose (FDG)--glucose containing a radioactive tag--which is injected into the patient. The FDG is highly concentrated in lymphoma cells and so the PET-CT scan will light-up in areas of lymphoma activity. An important goal of therapy is to 'switch-off' these lighted areas, obtaining a PET-negative remission.

By assessing imaging performed in three clinical trials, Dr Trotman and her French and Italian colleagues examined the link between PET-CT status and survival following first-line immunochemotherapy for advanced follicular lymphoma. Independent, masked reviewers evaluated the scans of 246 patients who underwent both PET-CT and traditional CT imaging within 3 months of their last dose of therapy.

The predictive power of PET-CT was much stronger than conventional CT, accurately identifying patients with an unfavourable prognosis--a PET-positive population with a high rate of disease progression and an almost seven fold increased risk of death--in whom the cancer should be closely monitored. PET-CT also identified that the 83% of patients who achieved PET-negativity had a reassuringly favourable prognosis, with average remission duration beyond 6 years.

According to Prof Trotman, "Our study shows that PET-CT is much better in evaluating treatment response and is an early predictor of survival. This greater accuracy will assist physicians to more effectively monitor their patients. We expect this research will result in PET-CT imaging replacing CT, becoming the new gold standard to evaluate patients with follicular lymphoma after treatment. Importantly, it will be a platform for future studies of response-adapted therapies aimed to improve the poor outcomes for those patients who remain PET positive."*

Writing in a linked Comment, Professor Bruce Cheson, Deputy Chief, Hematology-Oncology and Head of Hematology at Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA, says, "Trotman and colleagues' results might lead to several clinical research opportunities. One such possibility would be to assess if an early reaction to the PET scan result improves patient outcome. Thus, patients with a positive PET scan after induction therapy could be randomly assigned to either deferred treatment until disease progression or immediate intervention. A preferable alternative would be to introduce a unique agent at that time, such as the newly developed small molecules (eg, idelalisib, ibrutinib, or ABT-199) in a novel combination."
These results will be discussed at the International Workshop on PET in Lymphoma held in Menton, France, 18-20th September, 2014.

The Lancet Haematology is a new online journal launching in October 2014 that will build on The Lancet journals' rich history of publishing high-impact research covering the breadth of clinical haematology. As an exclusively online publication, the journal publishes research articles, linked commentary, and correspondence related to previous content. The journal accepts clinical research articles that advocate change in, or illuminate, haematological clinical practice. See for more details.

Notes to Editors:

This study was funded by Groupe d'Etude des Lymphomes de l'Adulte (Paris, France), now LYSA (Lymphoma Study Association), Direction de la Recherche Clinique de l'Assistance Publique-Hôpitaux de Paris, Fondazione Italiana Linfomi, and the Italian Ministry of Health.

*Quotes direct from author and cannot be found in text of Article.

The Lancet

Related Lymphoma Articles from Brightsurf:

Oncotarget: An integrative microenvironment approach for follicular lymphoma
Oncotarget Volume 11, Issue 33 features Figure 8, ''Haplotype estimates in follicular lymphoma patients,'' by Assis-Mendonça, et al. which reported that the authors tested associations between SNPs, clinicopathological features and TME composition, and proposed survival models in R-CHOP/R-CVP-treated patients.

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

A new immunotherapeutic agent for children and adolescents with advanced lymphoma
The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine.

Lymphoma's different route revealed
Researchers at the MDC observe the very early stages of blood vessel development in lymph node tumors.

Old weapon, new target: Dasatinib against angioimmunoblastic T-cell lymphoma
Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma is highly dependent on T-Cell Receptor Signaling.

Suspect eliminated as a therapeutic target in B cell lymphoma
Australian researchers have narrowed the focus on which survival proteins are important for the survival of B cell lymphomas, eliminating the protein BCL-W from the 'suspect list'.

New factor in the development of childhood lymphoma
The immune system is highly complex and a detailed understanding of many underlying mechanisms is still lacking.

Antibiotics can inhibit skin lymphoma
New research from the LEO Foundation Skin Immunology Research Center at the University of Copenhagen shows, surprisingly, that antibiotics inhibit cancer in the skin in patients with rare type of lymphoma.

Association of BRCA2 mutations with risk of childhood lymphoma
This research letter reports on the association of BRCA2 gene mutations and potential risk for pediatric or adolescent lymphoma.

Why Hodgkin's lymphoma cells grow uncontrollably
Although classical Hodgkin's lymphoma is generally easily treatable today, many aspects of the disease still remain a mystery.

Read More: Lymphoma News and Lymphoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to